The risk of oral cavity cancer was determined in relation to serological levels of iron; vitamins A, B2, C, E; zinc; thiamin; and glutathione (GSH). The study included 65 hospitalized patients with oral cancer and 85 matched controls. In comparing the highest to the lowest tertiles, the risk was odds ratio (OR) = 0.3 [95% confidence interval (CI) = 0.1-0.6] for iron; 3.2 (95% CI = 1.3-8.1) for total iron binding capacity (TIBC), which measures the concentration of the iron delivery protein transferrin; and 0.4 (95% CI = 0.2-0.9) for transferrin saturation (iron/TIBC × 100). These associations were stronger in never smokers than in ever smokers. The risk associated with the iron storage protein ferritin was significantly elevated, but this association could reflect disease-related inflammation or comorbidity. The OR for GSH was 0.4 (95% CI = 0.1-0.9), and the OR for GSH reductase activity coefficient (indicative of riboflavin deficiency) was 1.6 (95% CI = 1.3-3.7). These findings suggest that mild iron deficiency and low GSH levels, which are associated with increased oxidative stress, increase the risk of oral cavity cancer.
INTRODUCTION
The annual incidence of oral and pharyngeal cancer is approximately 75,000 in the United States (1) and 615,000 worldwide (2) . The major risk factors for oral squamous cell carcinoma are cigarette smoking and chronic alcohol consumption (3) (4) (5) (6) and low dietary intake of fruits (7, 8) .
The role of nutrition in oral cancer is not well understood, and one aspect of diet that has not been widely studied is iron metabolism. Iron is an essential nutrient, and iron deficiency is a common form of malnutrition worldwide. Low iron intake was first thought to be related to the high incidence of alimentary tract cancer in Swedish women during the early 20th century (9) . Many of these women presented with Plummer-Vinson (Patterson-Kelly) syndrome (10) , which is characterized by nutritional deficiencies including iron deficiency. The fortification of flour with iron in Sweden starting in 1944 led to a subsequent decline in Swedish oral cancer incidence rates (11) . There is a limited epidemiology on iron and oral cancer risk, but 3 studies have found a trend in the odds ratios (ORs) with decreasing dietary intake of iron (12) (13) (14) , and 1 study found a nonsignificant association between oral premalignancy and low iron intake in Indian women (15) . In experimental studies of 4-nitroquinoline-N-oxide exposed laboratory rats, the incidence of oral tumors was significantly elevated in iron deficient animals (16) . These findings were not confirmed in subsequent animal studies (17) .
Iron deficiency may cause oral cancer via the induction of oxidative stress. Iron deficiency produces free radicals and reactive oxygen species that potentially cause cellular injury (18) . Oxidative stress is often defined as the disturbance of equilibrium of prooxidant and antioxidant systems in favor of oxidation, leading to direct damage to cellular molecules such as DNA (19, 20) . Increased levels of oxidative stress have been associated with iron deficiency anemia in numerous studies and is thought to contribute to the pathogenesis of patients with this 475 disorder (21) (22) (23) . Oxidative stress has also been linked to the development of oral cancer (24) (25) (26) (27) , and diets high in antioxidant/nutrients have been associated with reduced risk for oral cancer, whereas increased risk has been associated with low intake of fruit (28) , ß-carotene, selenium, vitamin A, α-tocopherol, ascorbic acid, and lycopene (29, 30) . In chemoprevention trials of oral premalignancies and cancer, several of these micronutrient antioxidants exhibited antiproliferative effects; but data on tumor recurrence is more limited (31) .
Glutathione (GSH) is also likely associated with protection against oral cancer development because it is the major intracellular antioxidant (32) , detoxifies many carcinogens through Phase II conjugation, and maintains immune function by regulating mitogenic response and lymphocytic proliferation (33, 34) . Patients with oral cancer have been documented to have low blood GSH levels (35, 36) , although the relationship between blood GSH and oral cancer risk is unknown. One study found that high GSH intake in fruits and vegetables was associated with a reduced risk for oral cancer (37) .
This study was conducted to determine whether blood iron levels, glutathione, and other selected serum micronutrient/antioxidant levels are associated with the risk of oral cancer.
Because the percent of ingested iron that gets absorbed into the body is small and dietary intake of iron is not highly correlated with physiological levels (38) , the measurement of blood iron levels is necessary to establish their role in oral cancer risk. In measuring body iron status, we included both the functional and storage forms. Most iron in the body is bound to hemoglobin, which reflects the level of functional iron. About 30% is stored as ferritin, and a small percent is in the form of transferrin. The medical laboratory tests used most frequently to assess iron status include serum-free (unbound) iron; total iron binding capacity (TIBC), which indirectly measures the extent to which transferrin, the major iron-binding site in the serum, can be saturated; and transferrin saturation, which is the ratio of serum iron to TIBC. The liver increases production of transferrin in response to iron deficiency, and low serum iron and high TIBC together are indicative of iron deficiency and possibly anemia. The ratio of these 2 tests are also used to diagnose iron overload (e.g., hemochromatosis). The levels of TIBC can be affected by other factors such as malnutrition and inflammation. Ferritin is the major iron storage protein, and its levels reflect the levels of iron in the liver, spleen, and bone marrow. Decreased ferritin levels are indicative of iron deficiency, whereas increased levels can be indicative of iron overload, liver disease, infection, inflammation, and other disorders.
METHODS
A case-control study of oral cancer [International Classification of Diseases (9th revision) codes 141, 143-145, and 148-149] was conducted in collaboration with the Head and Neck Service of the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York. Eligible cases were men and women with newly diagnosed histopathologically confirmed primary cancer of the oral cavity, excluding carcinomas of the lip, salivary gland, and nasopharynx. A 2-stage stratified sampling scheme was developed. The first phase was based on enrolling all eligible participants, and the second phase included nonsmokers only to increase the sample size for this subgroup. The second phase of the study was conducted to clarify the possible role of iron in oral cancer. Because Plummer-Vinson syndrome was associated with oral cancer in primarily nonsmoking Swedish citizens, the possible carcinogenic effects of iron on oral epithelium may be more apparent in nonsmokers. Healthy controls were subjects without cancer who were recruited from the MSKCC Dental Service, which specializes in maxillofacial surgery. Control subjects were frequency matched to cases by age (within 10 yr), sex, and month of interview. All cases and controls were interviewed using a structured questionnaire that contained questions on smoking history, alcohol consumption, and occupation. Subjects signed a consent form that was approved by the Institutional Review Boards of MSKCC and the American Health Foundation. Approximately 90% of both cases and controls who were approached agreed to participate.
After the interview, the subjects were brought to a phlebotomy station for venipuncture. Fasting venous blood samples were obtained from an antecubital vein into two 10 ml Trace Metal Vacutainer tubes containing heparin as the anticoagulant (Becton Dickinson, Franklin Lakes, NJ) using a sterile 19-gauge needle. A sample of 0.5 ml of the whole blood was taken for GSH assay, and the remainder was centrifuged to separate plasma, erythrocytes, and buffy coat. Erythrocytes were washed in saline 3 times. Plasma and erythrocyte samples were then aliquoted for each assay, and all samples were immediately frozen and stored at −70
• C.
Blood Analyses
Serum iron was assayed spectrophtometrically by complexing ferrozine chromagen and measuring absorbance at 526 nm (39) . Serum TIBC was determined with an autoanalyzer by the method of Cook (40) . Serum transferrin saturation was calculated as serum iron/TIBC × 100. Serum ferritin was determined by a 2-site immunoradiometric assay (41) . Hemoglobin levels were measured in red cells and whole blood by the ferricyanidecyanide method as an indicator of anemia (42) . Plasma concentrations of retinol, α-tocopherol, and β-carotene were determined simultaneously by high-performance liquid chromatography (HPLC) (43) . Riboflavin status was assessed in red cells by measuring the in vitro activation of erythrocyte glutathione reductase activity by flavin adenine dinucleotide (FAD), and its levels are expressed as an activity coefficient (activity in the presence of added FAD/activity without added FAD) (44) . Thiamin status was assessed in red cells by measuring the in vitro activation of erythrocyte transketolase activity by thiamin pyrophosphate and expressed as an activity coefficient (activity in the presence of added thiamin pyrophosphate/activity without added thiamin pyrophosphate) (45) . Red blood cell folate content was determined using a radioimmunoassay (RIA; Diagnostic Products, Los Angeles, CA). The concentrations of zinc in erythrocytes and plasma were measured by flameless atomic absorption spectrophotometry using a Model 460 atomic absorption spectrophotometer equipped with an HGA-400 graphite furnace (Perkin-Elmer Corp., Norwalk, CT) (46) .
The ascorbic acid concentration of perchloric acid extracts of plasma was determined by HPLC with electrochemical detection (44) . Whole blood glutathione levels were determined by first deproteinating whole blood with 4-volumes of ice-cold 5% metaphosphoric acid. After centrifugation at 13,000 g for 2 min, glutathione content of supernatants were analyzed using an HPLC method with dual electrochemical detection (47) . Plasma cotinine levels were measured to validate smoking status (current vs. nonsmoking) using a modified RIA (48) .
Statistical Analysis
All analyses were performed using SAS statistical software (version 9.1; SAS Inst., Cary, NC). The blood micronutrient values were compared by smoking status, age, and other potential confounders using Student's t-test. The relationship between the blood iron measurements was determined by correlation coefficients. ORs and 95% confidence intervals (CIs) were calculated to determine the risk of oral cancer associated with tertiles of serum biomarkers. The tertiles were based on the levels of cases and controls combined. The effects of smoking on biomarker levels were determined by classifying ever smokers as having smoked at least 1 cigarette per day for ≥1 yr. Never smoking was defined as never having smoked or smoking cigarettes for <1 yr. Former smoking was defined as having quit at least 1 mo prior to the interview. Logistic regression models were used to calculate ORs and 95% CI. The models were adjusted for age, sex, and smoking status.
RESULTS
The study included 65 oral cancer cases. The most frequent site of the tumor was the tongue (50%), followed by the floor of the mouth (18%), gingiva (14%), and other areas (18%). A total of 85 subjects participated as controls. About 2/3 of all cases and controls were men, and the mean age was 58 in oral cancer cases and 54 in controls (Table 1) . A total of 17 cancer cases (26%) and 37 controls (44%) were never smokers. The reported smoking status (current vs. not current) was confirmed as 100% accurate using cotinine levels as the validation standard. A total of 14 (82%) of the never-smoking cases had tongue cancer, who accounted for all of the cases <40 yr of age. The mean age of all male never-smoking cases (41.3 yr ± 19.0) was substantially lower than female never smokers (63.7 yr ± 15.0) and in all ever smokers (61.6 yr ± 7.81).
When blood iron levels were classified according to clinically normal values, 3 controls and 12 cases had serum iron levels that fell below normal values (60-170 µg/dl); 9 controls and 1 case had clinically elevated levels. A total of 5 cases and controls fell below normal TIBC levels (<240-450), and 15 cases and 17 controls had elevated TIBC levels. About 25% of all subjects had clinically defined iron deficiency based on cutoff values of transferrin saturation (<15%). A total of 8 controls and 12 cases had greater than normal ferritin levels (e.g., >12-300 ng/dl). Hemoglobin levels were within normal ranges for all subjects and did not differ between cases and controls. Because serum ferritin increases with age, we examined the biomarkers of iron metabolism by age in cases and controls (Table 2) . No significant age differences were observed for the iron biomarkers except for ferritin levels, which were significantly increased in both men and women greater than age 50 yr. Among oral cancer cases, mean ferritin levels as well as other measures of iron did not vary significantly by the site of the tumor (Table 3) . Cigarette smoking status (current vs. not currently smoking) was not related to mean levels of iron measurements and most micronutrients (data not shown). Ascorbic acid levels were 20% lower, and plasma zinc levels were 11% lower in smokers compared to nonsmokers (P < 0.05), whereas glutathione reductase activity coefficients (a measure of riboflavin status) were 12% higher, and plasma zinc levels were 13% higher in smokers compared to nonsmokers (P < 0.05).
The mean levels of the iron measurements were compared between cases and controls separately for never smokers and ever smokers (Table 4) . In never smokers, mean free iron levels were 45% higher in controls than in cases (P < 0.002); however, no significant differences were observed in smokers. The mean levels of transferrin saturation were higher in controls vs. cases in both never smokers and smokers, but the difference was greater in never smokers (55%) than in smokers (28%). Mean ferritin levels were 51% higher in cases than controls among never smokers (P < 0.05) but were not significantly different among ever smokers. For the other blood micronutrients, we did not observe higher levels in nonsmoking controls vs. nonsmoking cases, although the levels of GSH in nonsmoking controls tended to be higher than in nonsmoking cases, whereas this difference was not quite as apparent in the smoking group. Table 5 shows the adjusted odds ratios for oral cancer associated with tertiles of blood iron biomarker levels. Despite differences in mean levels of various measures between cases and controls, the risk associated with the upper tertiles of exposure did not vary significantly by smoking status. After controlling for smoking, age, and other factors, the risk was significantly decreased in subjects with the highest tertile of both free iron and transferrin saturation compared to their lowest tertiles, respectively. In contrast, the highest levels of ferritin and TIBC were associated with a significantly increased risk of oral cancer. Although tests for homogeneity by ever-smoking status were not significant, the association with the highest tertile was stronger in never smokers (free iron, OR = 0.12; 95% CI = 0.02-0.71; and transferrin saturation, OR = 0.13; 95% CI = 0.02-0.82). The risk for the highest tertile of ferritin in never smokers was 5.8 (95% CI = 1.2-28). When blood iron levels were grouped into clinical diagnostic categories, a significant dose-response relationship was also observed between increasing risk for oral cancer and decreasing levels of iron [low (<60 µg/dl): OR = Table 6 shows the risk of oral cancer associated with blood levels of antioxidant micronutrients. Significantly decreased risk was observed for the highest tertile of blood glutathione (OR = 0.4, 95% CI = 0.1-0.9). Glutathione levels were not correlated with any of the 4 iron measurements. A significantly increased risk was observed for individuals with glutathione reductase activity coefficient >1.29 (indicative of riboflavin deficiency, a condition characterized by lesions of the skin, digestive tract surface, or nervous disorders; OR = 3.0, 95% CI = 1.3-7.0). No associations were observed for other micronutrients.
DISCUSSION
In this hospital-based, case-control population, increased risk for oral cancer was associated with nonanemic low iron levels. The risk was also associated with low blood GSH, suggesting that oxidative stress may be playing a role in oral cancer development.
There are several possible limitations that need to be considered when interpreting these results. First, the concentrations of the serum nutrients may not be indicative of long-term dietary patterns. This may limit the ability to make inferences and recommendations for prevention regarding dietary iron intake, although the advantage of biochemical measures is that they are not subject to recall biases like food frequency assessments. Second, diurnal variation in blood biomarker levels, as have been observed for serum iron and transferrin saturation levels, may have affected these results, although fasting blood samples were obtained to help control for circadian fluctuations. Iron determinations restricted to a specific time of day does not seem to improve the reliability of iron test results (49) . Third, biomarkers levels in cases were measured postdiagnostically and may reflect recent changes in dietary habits. However, our questionnaire data found that subjects did not change their dietary habits after the diagnosis of cancer. Further, the blood levels of numerous diet-related micronutrients were not different between cases and controls. The development of cancer or its treatment might affect the serum levels of blood nutrients including iron measurements. To help control for treatment effects, the case patients in this study were enrolled postsurgically but prior to chemotherapy and radiation therapy. Although it is possible that the development of oral cancer alters the regulation of iron metabolism and affects the serum levels of iron, mean levels of serum iron were also lower in a small sample of patients with precancerous oral lesions (data not shown).
Our findings on iron are consistent with the correlation between the iron deficiency condition Plummer-Vinson syndrome and the high rates of oral cancer in Swedish women before 1950 (9) and with more recent case-control studies that have linked low iron intake with oral cancer risk (12) (13) (14) . The associations between levels of blood iron and oral cancer risk was more pronounced in never smokers, which might be expected if a true association exists because smoking is such a powerful risk factor for oral cancer and might mask the ability to detect nutritional effects.
In contrast to serum iron, ferritin levels were higher in cases and controls. Although a low ferritin level is a diagnostic criteria for iron deficiency, high ferritin levels can occur in response to numerous factors including infection, inflammation, and chronic disease (50) . Thus, ferritin levels can be increased, even in the presence of an iron deficiency condition (51) . Ferritin levels are known to be increased in patients with oral disease (52, 53) , breast cancer, Hodgkin's disease, and surgical tissue injury (54) (55) (56) (57) .
The findings on iron biomarkers do not appear to be due to confounding or selection bias. The higher iron levels in women vs. men and the lack of an effect of age on transferrin saturation in this study are consistent with previous reports (58, 59) . The lowered levels of vitamin C in smokers are also consistent with other data (60) . In reviewing the age distribution of the male cases, the younger age of never smokers is also consistent with reports of increased incidence of tongue cancer in nonsmoking young men (61, 62) . The levels of TIBC were somewhat higher here than in other studies (41, 63, 64) . Consequently, the mean transferrin saturation percent in controls (25.8%) was lower than that reported for normal healthy subjects. Arithmetic mean values in other studies have ranged from about 31-35% (41, 64) . The geometric mean of 23.8% was slightly lower than that reported for controls in an epidemiologic study of colon cancer (25.8%) (63) . Increasing blood glutathione levels were significantly associated with a decreased risk for oral cancer in our data. One study found an association between increased dietary intake of GSH from fruits and vegetables and decreased risk for oral cancer (OR = 0.5) (65) . As the most abundant antioxidant in nearly all cells and tissues including the oral epithelium, glutathione is the first line of defense against oxidative stress and other cellular insults (66) . Glutathione conjugation is a major pathway for the detoxification of carcinogens including polycyclic aromatic hydrocarbons thought to be involved in the development of aerodigestive tract cancers (67) . Consequently, glutathione is thought to play an important protective role against numerous diseases including cancer (68) . A direct role for glutathione in the inhibition of oral carcinogenesis was suggested by the finding that oral administration of glutathione was associated with a reduction in dimethylbenz[a]anthracene-induced cheek pouch tumors in the hamster (69, 70) , and numerous laboratory findings have found that GSH depletion increases the incidence of experimentally induced oral cancer.
The finding that riboflavin deficiency, as measured by glutathione reductase activity coefficient, is associated with increased risk for oral cancer is consistent with previous findings (12, 71) . It is of interest that many of the clinical symptoms of riboflavin deficiency are similar to those observed in iron deficiency (72) (73) (74) . Further, riboflavin status can markedly influence iron economy due to the specific role of flavins in the mobilization of iron from its intracellular carrier protein ferritin (75, 76) . Riboflavin deficiency can also impair the gastrointestinal absorption of iron (77) . Feeding mice a diet deficient in riboflavin causes morphological alterations in skin and upper alimentary tract epithelium that are similar to those observed in patients suffering from Plummer-Vinson disease (78) . Riboflavin deficiency was also associated with enhanced development of dimethylbenzeanthracene-induced skin tumors in mice (79) , an effect that may be related to enhanced carcinogen activating capacity (80) .
Previous studies have generally observed that vitamin C intake protects against the development of oral cancer (29) . We observed no significant association with serum vitamin C levels after adjustment for smoking. It is possible that we did not detect an association because the effects of vitamin C seem to be dependent on the levels and combinations of other micronutrients.
There have been few reports of prediagnostic serum antioxidant micronutrient levels and oral cancer risk. In the Iowa Women's Health Study that included 33 women who developed oral, pharyngeal, or esophageal cancer (81), the combined higher intakes of carotene and vitamins C and E were associated with lower risks of these cancers. In a Japanese study with 48 cases of leukoplakia, high serum levels of β-carotene significantly reduced the risk in men but not in women (82) . In a nested case-control study of 28 cases with oral or pharyngeal cancer and 112 matched controls, dose-related increased risks were found with lower levels of all individual serum carotenoids and especially β-carotene (83) . In contrast, the risks were significantly elevated with increasing serum levels of γ -tocopherol and selenium. A nested study of 16 oral/pharyngeal cases in Japanese men found reduced risks associated with serum α-carotene and β-carotene.
Oxidative stress may be the critical factor that links low body iron stores, riboflavin status, and GSH levels with increased risk for oral cancer. Oxidative stress has been associated with iron deficiency in numerous studies (21) (22) (23) and is thought to be an important contributor to oral carcinogenesis (24) (25) (26) (27) . As described previously, GSH represents the major intracellular antioxidant, and maintenance of its levels is dependant on riboflavin, which, through its metabolite FAD, serves as a key cofactor for the enzyme, glutathione reductase, responsible for maintaining GSH in its reduced state (84) . The finding that other antioxidant/nutrient levels were not associated with oral cancer risk may be due to their dependency on diet. Although GSH levels can be related to diet, regulation of their levels in vivo are dependant on a complex endogenous regulatory system involving numerous metabolic pathways (85) . Our previous results indicate that blood GSH levels are an accurate biomarker of body status that are not influenced by acute changes in diet or environmental exposures (86) (87) (88) .
